Selinexor
Xpovio · XPO1 (nuclear export) inhibitor
Hyponatremia is common and dose-limiting.
Javlor · VFL
Vinca alkaloid · approved 2009 · 5 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A fluorinated vinca alkaloid used precisely because patients are too renally impaired for cisplatin — its renal story is careful dose-banding, not direct kidney injury.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
No strong direct nephrotoxic signal. Vinflunine is given to renally impaired, cisplatin-unfit patients with a defined dose-reduction schema, and tolerability in renal impairment mirrors that of patients with normal renal function once dose-banded. SIADH/hyponatremia is a class-level vinca-alkaloid effect rather than a quantified vinflunine-specific rate. Reported rate: grade >=3 hyponatremia in 12% — 51 patients with relapse-sensitive or relapse-refractory small cell lung cancer treated with single-agent vinflunine… (Spigel 2010, PMID 20521355).Source: Spigel et al., J Thorac Oncol 2010
Electrolyte/prerenal effects within days of a cycle.
Distilled from: “Electrolyte/prerenal effects can appear within days of a cycle; PK accumulation in renal impairment is immediate but mitigated by protocol dose reduction.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Grade 3/4 hyponatremia in 12% on single-agent vinflunine 320 mg/m2 (relapsed SCLC phase II)
Inappropriate water retention at the collecting duct — high-dose cyclophosphamide.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Tap a signature to trace where it strikes the nephron.
Representative grade ≥3 incidence
Electrolyte Disturbance strikes: Distal Tubule / Collecting Duct.
Electrolyte Disturbance
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Vinflunine is a third-generation, bifluorinated vinca alkaloid that binds tubulin and inhibits microtubule dynamics, arresting cells in mitosis (M phase) and triggering apoptosis. It is approved as second-line therapy for advanced/metastatic urothelial (transitional-cell) carcinoma after platinum failure, and is studied in first-line cisplatin-ineligible disease — a population defined largely by renal impairment.
Class-level context for the major non-renal toxicities of the Vinca alkaloid class.
Ophthalmic
Keratopathy, uveitis, retinopathy
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
5 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Everything below is FAERS — adverse events someone chose to report, about 53 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Counted by the report's active-substance field, which FAERS fills almost only on reports received from 2013 on, so these figures describe reports since then, not the agent's whole history.
Reported with a death outcome
7 of 53 reports
Reported with hospitalization
17 of 53 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Vinflunine sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Xpovio · XPO1 (nuclear export) inhibitor
Hyponatremia is common and dose-limiting.
Zegfrovy · EGFR exon20 TKI
2025 EGFR exon20 TKI; renal magnesium wasting (SIADH-pattern hyponatremia possible).
Nolvadex · SERM
Hypercalcemia flare; rare hyponatremia.
Somatuline · Somatostatin analog
Kidney-neutral (CLARINET: diarrhea dominant); increased exposure in renal impairment.
Daurismo · Hedgehog (SMO) inhibitor
QT prolongation and muscle spasms; AML.
Nubeqa · Androgen receptor inhibitor (ARSI)
Not nephrotoxic; exposure rises in severe renal impairment, so consider dose adaptation.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.